Retrospective study of the inhibitory effect of paroxetine on the cerebral aneurysm growth and recurrence after endovascular treatment for cerebral aneurysms

Retrospective study of the inhibitory effect of paroxetine on the cerebral aneurysm growth and recurrence after endovascular treatment for cerebral aneurysms - Drug for aneurysm study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042109

Enrollment

500

Registered

2020-10-14

Start date

2020-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cerebral aneurysm

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Unruptured saccular cerebral aneurysm with a major axis of 3 mm or more or saccular cerebral aneurysm with a major axis of 3 mm or more that underwent coil embolization (ruptured and unruptured cerebral aneurysm) (2) Cases in which cerebrovascular imaging (MRA, 3DCTA, or cerebrovascular angiography) has been performed at least twice (3) Cases in which the interval between the first and final cerebrovascular imaging tests is at least half a year (4) Cases in which paroxetine was continuously taken during the first and final cerebrovascular imaging examinations, and cases in which paroxetine was not taken at all in the control group during the period. (5) In cases of coil embolization, cases in which cerebrovascular imaging at the time of surgery can be obtained (6) Cases aged 20 years or older at the time of the first cerebrovascular imaging test

Exclusion criteria

Exclusion criteria: (1) Cases of dissecting cerebral aneurysm (2) Cases of bacterial cerebral aneurysm (3) Cases of cerebrovascular imaging test results where the size of the cerebral aneurysm and the presence or absence of recurrence after coil embolization cannot be determined (4) Cases in which the principal investigator or the research coordinator judged that participation in this study was not appropriate

Design outcomes

Primary

Measure	Time frame
To compare the rate of cerebral aneurysm growth between unruptured cerebral aneurysms who were taking paroxetine and those who were not taking paroxetine.	—

Secondary

Measure	Time frame
To compare the postoperative recanalization rate between patients who underwent coil embolization of a cerebral aneurysm who were taking paroxetine and those who were not taking paroxetine.	—

Countries

Japan

Contacts

Public ContactDrug for aneurysm Study Secretariat

National Hospital Organization Kyoto Medical Center Department of Neurosurgery

drug.for.aneurysm@gmail.com075-641-9161

Outcome results